AR077977A1 - Compuestos y composiciones como inhibidores de cinasa de proteina - Google Patents
Compuestos y composiciones como inhibidores de cinasa de proteinaInfo
- Publication number
- AR077977A1 AR077977A1 ARP100103125A ARP100103125A AR077977A1 AR 077977 A1 AR077977 A1 AR 077977A1 AR P100103125 A ARP100103125 A AR P100103125A AR P100103125 A ARP100103125 A AR P100103125A AR 077977 A1 AR077977 A1 AR 077977A1
- Authority
- AR
- Argentina
- Prior art keywords
- carbon atoms
- alkyl
- halogen
- substituted
- cycloalkyl
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 2
- 229940045988 antineoplastic drug protein kinase inhibitors Drugs 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
- 239000003909 protein kinase inhibitor Substances 0.000 title 1
- 125000004432 carbon atom Chemical group C* 0.000 abstract 24
- 125000000217 alkyl group Chemical group 0.000 abstract 17
- 229910052736 halogen Inorganic materials 0.000 abstract 14
- 125000005843 halogen group Chemical group 0.000 abstract 8
- 150000002367 halogens Chemical class 0.000 abstract 6
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 4
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 4
- 125000003545 alkoxy group Chemical group 0.000 abstract 2
- 229910052799 carbon Inorganic materials 0.000 abstract 2
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 abstract 2
- 125000001424 substituent group Chemical group 0.000 abstract 2
- KKVYYGGCHJGEFJ-UHFFFAOYSA-N 1-n-(4-chlorophenyl)-6-methyl-5-n-[3-(7h-purin-6-yl)pyridin-2-yl]isoquinoline-1,5-diamine Chemical compound N=1C=CC2=C(NC=3C(=CC=CN=3)C=3C=4N=CNC=4N=CN=3)C(C)=CC=C2C=1NC1=CC=C(Cl)C=C1 KKVYYGGCHJGEFJ-UHFFFAOYSA-N 0.000 abstract 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 abstract 1
- 101100381978 Mus musculus Braf gene Proteins 0.000 abstract 1
- 125000002947 alkylene group Chemical group 0.000 abstract 1
- -1 and R1a is H Chemical group 0.000 abstract 1
- 125000004429 atom Chemical group 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Immunology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US23808309P | 2009-08-28 | 2009-08-28 | |
| US31306110P | 2010-03-11 | 2010-03-11 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR077977A1 true AR077977A1 (es) | 2011-10-05 |
Family
ID=42829939
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP100103125A AR077977A1 (es) | 2009-08-28 | 2010-08-26 | Compuestos y composiciones como inhibidores de cinasa de proteina |
Country Status (19)
| Country | Link |
|---|---|
| US (3) | US8242260B2 (enExample) |
| EP (1) | EP2470528B1 (enExample) |
| JP (1) | JP5726190B2 (enExample) |
| KR (1) | KR101714107B1 (enExample) |
| CN (1) | CN102596937B (enExample) |
| AR (1) | AR077977A1 (enExample) |
| AU (1) | AU2010288455B2 (enExample) |
| BR (1) | BR112012004448A2 (enExample) |
| CA (1) | CA2771673C (enExample) |
| EA (1) | EA020479B1 (enExample) |
| ES (1) | ES2527176T3 (enExample) |
| IN (1) | IN2012DN00869A (enExample) |
| JO (1) | JO3007B1 (enExample) |
| MX (1) | MX2012002542A (enExample) |
| PL (1) | PL2470528T3 (enExample) |
| PT (1) | PT2470528E (enExample) |
| TW (1) | TWI487701B (enExample) |
| UY (1) | UY32859A (enExample) |
| WO (1) | WO2011023773A1 (enExample) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JO3002B1 (ar) | 2009-08-28 | 2016-09-05 | Irm Llc | مركبات و تركيبات كمثبطات كيناز بروتين |
| CA2789696C (en) | 2010-02-25 | 2017-11-07 | Dana-Farber Cancer Institute, Inc. | Braf mutations conferring resistance to braf inhibitors |
| US9498471B2 (en) | 2011-10-20 | 2016-11-22 | The Regents Of The University Of California | Use of CDK9 inhibitors to reduce cartilage degradation |
| RU2622015C2 (ru) | 2011-11-11 | 2017-06-08 | Новартис Аг | Способ лечения пролиферативного заболевания |
| EP3449911B8 (en) | 2011-11-23 | 2025-07-23 | Array BioPharma Inc. | Pharmaceutical formulations |
| US9408885B2 (en) | 2011-12-01 | 2016-08-09 | Vib Vzw | Combinations of therapeutic agents for treating melanoma |
| WO2014047330A1 (en) * | 2012-09-19 | 2014-03-27 | Jean-Michel Vernier | Novel raf kinase inhibitors |
| US9242969B2 (en) * | 2013-03-14 | 2016-01-26 | Novartis Ag | Biaryl amide compounds as kinase inhibitors |
| CA2912568A1 (en) * | 2013-05-30 | 2014-12-04 | Plexxikon Inc. | Compounds for kinase modulation, and indications therefor |
| MX2015016771A (es) | 2013-06-25 | 2016-03-31 | Squibb Bristol Myers Co | Compuestos de carbazol carboxamida utiles como inhibidores de cinasa. |
| AR096721A1 (es) | 2013-06-25 | 2016-01-27 | Bristol Myers Squibb Co | Compuestos de tetrahidrocarbazol y carbazol carboxamida sustituidos |
| EP3038622B1 (en) * | 2013-08-28 | 2018-05-30 | Medivation Technologies LLC | Heterocyclic compounds and methods of use |
| GB2517988A (en) * | 2013-09-09 | 2015-03-11 | Redx Pharma Ltd | Compounds |
| UY36294A (es) | 2014-09-12 | 2016-04-29 | Novartis Ag | Compuestos y composiciones como inhibidores de quinasa |
| EP3206749B1 (en) | 2014-10-14 | 2021-09-08 | The Regents of the University of California | The cdk9 and brd4 inhibitors flavopiridol and jq1 to inhibit cartilage inflammation |
| CN104402920B (zh) * | 2014-11-27 | 2018-04-03 | 河南科技学院 | 一种合成2‑卤代‑3‑频那醇硼酸酯‑5‑氯苯胺的方法 |
| EP3515446B1 (en) | 2016-09-19 | 2023-12-20 | Novartis AG | Therapeutic combinations comprising a raf inhibitor and a erk inhibitor |
| JP7341060B2 (ja) | 2017-02-10 | 2023-09-08 | アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル | Ｍａｐｋ経路の活性化に関連付けられる癌の処置のための方法及び医薬組成物 |
| JP7309614B2 (ja) | 2017-05-02 | 2023-07-18 | ノバルティス アーゲー | 組み合わせ療法 |
| EP3732285A1 (en) | 2017-12-28 | 2020-11-04 | Tract Pharmaceuticals, Inc. | Stem cell culture systems for columnar epithelial stem cells, and uses related thereto |
| WO2020124397A1 (en) * | 2018-12-19 | 2020-06-25 | Inventisbio Shanghai Ltd. | C-terminal src kinase inhibitors |
| EP3969449B1 (en) | 2019-05-13 | 2025-02-12 | Novartis AG | New crystalline forms of n-(3-(2-(2-hydroxyethoxy)-6-morpholinopyridin-4-yl)-4-methvlphenyl)-2(trifluoromethyl)isonicotinamide as raf inhibitors for the treatment of cancer |
| US20230303551A1 (en) * | 2020-08-13 | 2023-09-28 | Albert Einstein College Of Medicine | N-cyclyl-sulfonamides useful for inhibiting raf |
| IL315603A (en) | 2022-03-28 | 2024-11-01 | Nikang Therapeutics Inc | Sulfonamido derivatives as cycle-dependent KINASE 2 inhibitors |
| WO2023240024A1 (en) | 2022-06-08 | 2023-12-14 | Nikang Therapeutics, Inc. | Sulfamide derivatives as cyclin-dependent kinase 2 inhibitors |
| WO2025072462A1 (en) | 2023-09-27 | 2025-04-03 | Nikang Therapeutics, Inc. | Sulfonamide derivatives as cyclin-dependent kinase 2 inhibitors |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2659739A (en) | 1950-04-14 | 1953-11-17 | Eastman Kodak Co | 1-hydroxy-4-beta-cyanopropylamino-anthraquinone and process for preparing same |
| US6358932B1 (en) | 1994-05-31 | 2002-03-19 | Isis Pharmaceticals, Inc. | Antisense oligonucleotide inhibition of raf gene expression |
| US6391636B1 (en) | 1994-05-31 | 2002-05-21 | Isis Pharmaceuticals, Inc. | Antisense oligonucleotide modulation of raf gene expression |
| US6037136A (en) | 1994-10-24 | 2000-03-14 | Cold Spring Harbor Laboratory | Interactions between RaF proto-oncogenes and CDC25 phosphatases, and uses related thereto |
| US5717100A (en) | 1995-10-06 | 1998-02-10 | Merck & Co., Inc. | Substituted imidazoles having anti-cancer and cytokine inhibitory activity |
| GB2306108A (en) * | 1995-10-13 | 1997-04-30 | Merck & Co Inc | Treatment of Raf-mediated cancers with imidazole derivatives |
| US6281193B1 (en) | 1996-05-23 | 2001-08-28 | Applied Research Systems Ars Holding N.V. | Compounds that inhibit the binding of RAF-1 or 14-3-3 proteins to the beta chain of IL-2 receptor, and pharmaceutical compositions containing same |
| AR012634A1 (es) | 1997-05-02 | 2000-11-08 | Sugen Inc | Compuesto basado en quinazolina, composicion famaceutica que lo comprende, metodo para sintetizarlo, su uso, metodos de modulacion de la funcion deserina/treonina proteinaquinasa con dicho compuesto y metodo in vitro para identificar compuestos que modulan dicha funcion |
| US6187799B1 (en) | 1997-05-23 | 2001-02-13 | Onyx Pharmaceuticals | Inhibition of raf kinase activity using aryl ureas |
| GB9716557D0 (en) | 1997-08-06 | 1997-10-08 | Glaxo Group Ltd | Benzylidene-1,3-dihydro-indol-2-one derivatives having anti-cancer activity |
| US6022884A (en) | 1997-11-07 | 2000-02-08 | Amgen Inc. | Substituted pyridine compounds and methods of use |
| US6204467B1 (en) | 1998-03-24 | 2001-03-20 | Ford Global Technologies, Inc. | Method and apparatus for resistive welding |
| US7351834B1 (en) | 1999-01-13 | 2008-04-01 | Bayer Pharmaceuticals Corporation | ω-Carboxyaryl substituted diphenyl ureas as raf kinase inhibitors |
| WO2002018654A1 (en) | 2000-08-30 | 2002-03-07 | The Board Of Trustees Of The University Of Arkansas | Induction of ldl receptor expression by extracellular-signal regulated kinase, erk-1/2 |
| CN100519539C (zh) | 2002-03-13 | 2009-07-29 | 阵列生物制药公司 | 作为mek抑制剂的n3烷基化苯并咪唑衍生物 |
| US6644516B1 (en) | 2002-11-06 | 2003-11-11 | Continental Afa Dispensing Company | Foaming liquid dispenser |
| WO2006090169A1 (en) | 2005-02-25 | 2006-08-31 | Kudos Pharmaceuticals Limited | 2,4-diamino-pyridopyrimidine derivatives and their use as mtor inhibitors |
| US20100130473A1 (en) | 2005-02-25 | 2010-05-27 | Marc Geoffrey Hummersone | Compounds |
| CA2628920C (en) | 2005-11-22 | 2015-12-29 | Kudos Pharmaceuticals Limited | Pyrido-,pyrazo- and pyrimido-pyrimidine derivatives as mtor inhibitors |
| JP2009523161A (ja) | 2006-01-11 | 2009-06-18 | アストラゼネカ アクチボラグ | モルホリノピリミジン誘導体と療法におけるその使用 |
| KR101438245B1 (ko) | 2006-08-23 | 2014-09-04 | 쿠도스 파마슈티칼스 리미티드 | Ｍｔｏｒ 억제제로서의 2-메틸모르폴린 피리도-, 피라조- 및 피리미도-피리미딘 유도체 |
| TW200922582A (en) | 2007-08-20 | 2009-06-01 | Organon Nv | N-benzyl, N'-arylcarbonylpiperazine derivatives |
| CN102015686B (zh) | 2008-03-21 | 2014-07-02 | 诺华股份有限公司 | 杂环化合物及其用途 |
| UA103319C2 (en) | 2008-05-06 | 2013-10-10 | Глаксосмитклайн Ллк | Thiazole- and oxazole-benzene sulfonamide compounds |
| CN102105459B (zh) * | 2008-07-24 | 2014-09-10 | 内尔维阿诺医学科学有限公司 | 作为蛋白激酶抑制剂的3,4-二芳基吡唑类 |
-
2010
- 2010-08-24 US US12/862,418 patent/US8242260B2/en not_active Expired - Fee Related
- 2010-08-26 MX MX2012002542A patent/MX2012002542A/es active IP Right Grant
- 2010-08-26 CA CA2771673A patent/CA2771673C/en not_active Expired - Fee Related
- 2010-08-26 AU AU2010288455A patent/AU2010288455B2/en not_active Ceased
- 2010-08-26 PL PL10745280T patent/PL2470528T3/pl unknown
- 2010-08-26 CN CN201080038235.XA patent/CN102596937B/zh active Active
- 2010-08-26 BR BR112012004448A patent/BR112012004448A2/pt not_active Application Discontinuation
- 2010-08-26 ES ES10745280.7T patent/ES2527176T3/es active Active
- 2010-08-26 EP EP10745280.7A patent/EP2470528B1/en active Active
- 2010-08-26 WO PCT/EP2010/062495 patent/WO2011023773A1/en not_active Ceased
- 2010-08-26 JO JOP/2010/0298A patent/JO3007B1/ar active
- 2010-08-26 JP JP2012526067A patent/JP5726190B2/ja active Active
- 2010-08-26 EA EA201200323A patent/EA020479B1/ru not_active IP Right Cessation
- 2010-08-26 AR ARP100103125A patent/AR077977A1/es unknown
- 2010-08-26 KR KR1020127007838A patent/KR101714107B1/ko not_active Expired - Fee Related
- 2010-08-26 IN IN869DEN2012 patent/IN2012DN00869A/en unknown
- 2010-08-26 PT PT107452807T patent/PT2470528E/pt unknown
- 2010-08-27 UY UY0001032859A patent/UY32859A/es not_active Application Discontinuation
- 2010-08-27 TW TW099128938A patent/TWI487701B/zh not_active IP Right Cessation
-
2012
- 2012-05-16 US US13/473,230 patent/US8563553B2/en active Active
-
2013
- 2013-09-10 US US14/022,540 patent/US8859548B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| AU2010288455A1 (en) | 2012-02-23 |
| CA2771673C (en) | 2016-07-12 |
| BR112012004448A2 (pt) | 2017-05-30 |
| CN102596937B (zh) | 2014-02-12 |
| PT2470528E (pt) | 2014-12-29 |
| EP2470528A1 (en) | 2012-07-04 |
| IN2012DN00869A (enExample) | 2015-07-10 |
| TWI487701B (zh) | 2015-06-11 |
| JP2013503139A (ja) | 2013-01-31 |
| US20140011825A1 (en) | 2014-01-09 |
| EA201200323A1 (ru) | 2012-09-28 |
| EP2470528B1 (en) | 2014-10-01 |
| ES2527176T3 (es) | 2015-01-21 |
| CA2771673A1 (en) | 2011-03-03 |
| UY32859A (es) | 2011-03-31 |
| EA020479B1 (ru) | 2014-11-28 |
| US8859548B2 (en) | 2014-10-14 |
| US20120225899A1 (en) | 2012-09-06 |
| TW201111365A (en) | 2011-04-01 |
| WO2011023773A1 (en) | 2011-03-03 |
| PL2470528T3 (pl) | 2015-03-31 |
| JP5726190B2 (ja) | 2015-05-27 |
| US8242260B2 (en) | 2012-08-14 |
| US20110052578A1 (en) | 2011-03-03 |
| MX2012002542A (es) | 2012-04-02 |
| CN102596937A (zh) | 2012-07-18 |
| KR20120092577A (ko) | 2012-08-21 |
| JO3007B1 (ar) | 2016-09-05 |
| KR101714107B1 (ko) | 2017-03-08 |
| US8563553B2 (en) | 2013-10-22 |
| AU2010288455B2 (en) | 2013-01-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR077977A1 (es) | Compuestos y composiciones como inhibidores de cinasa de proteina | |
| AR072952A1 (es) | Compuestos de 2-imino-3-metilpirrolopirimidinona fenilo-sustituida como inhibidores de bace-1, composiciones y su uso | |
| AR077975A1 (es) | Derivados de pirazol pirimidina y composiciones como inhibidores de cinasa de proteina | |
| EA201690019A1 (ru) | Производное аминотриазина и содержащая его фармацевтическая композиция | |
| PE20140192A1 (es) | Derivados de bencimidazol como inhibidores de cinasa pi3 | |
| AR098912A1 (es) | Inhibidores de syk | |
| PE20141598A1 (es) | Derivados de dihidro-benzo-oxazina y dihidro-pirido-oxazina | |
| AR078045A1 (es) | Derivados de pirimidina, composiciones farmaceuticas que los comprenden y su uso en la fabricacion de un medicamento para el tratamiento del cancer | |
| AR087668A1 (es) | Derivados de oxazina y su uso en el tratamiento de enfermedades | |
| EA200970510A1 (ru) | Гетеромоноциклическое соединение и его применение | |
| CY1118572T1 (el) | Παραγωγο κυκλοαλκανιου | |
| PE20160844A1 (es) | Compuestos triciclicos como agentes anticancerigenos | |
| AR053120A1 (es) | Aminopiridinas como inhibidores de beta secretasa | |
| PE20110150A1 (es) | Amidofenoxiindazoles como inhibidores de c-met | |
| AR087915A1 (es) | N-(3-(2-amino-6,6-difluor-4,4a,5,6,7,7a-hexahidro-ciclopenta-[e][1,3]oxazin-4-il)-fenil)-amidas como inhibidores de la bace1 | |
| AR083849A1 (es) | Antagonistas de mdm2 de espiro-oxindol | |
| UY30498A1 (es) | Nueva clase de compuestos de benzimidazolilo, sus sales, composiciones farmacéuticas conteniéndolos y aplicaciones | |
| AR085615A1 (es) | Derivados de fluoropiridinona utiles como agentes antibacterianos y composiciones farmaceuticas que los contienen | |
| AR051485A1 (es) | Pirazolo pirimidinas 1,4-sustituidas como inhibidores de quinasa | |
| AR080779A1 (es) | Pirrolopirazina como inhibidores quinasa, composiciones farmaceuticas que los contienen y sus aplicaciones | |
| EA201001682A1 (ru) | Производные фенил- и бензодиоксинилзамещенных индазолов | |
| BR112014006660A2 (pt) | novos derivados de dihidroquinolina-2-ona bicíclicos | |
| AR082029A1 (es) | Derivados de heterociclos nitrogenados, composiciones y metodos para modular la via de señalizacion de wnt | |
| PE20080409A1 (es) | Compuestos que modulan en el receptor cb2 | |
| AR074089A1 (es) | Antagonistas de cicloalcano (b) azaindol de los receptores de la postaglandina d2 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |